SCHEMBL27996366

SCHEMBL27996366

NC(=O)c1cncc(-c2cncc(-c3ccc(OC(F)(F)F)cc3)c2)c1

nearest known ligand 0.60

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SCN10A Q9Y5Y9 1/20 0.60
MAP4K4 O95819 3/20 0.58
ABL1 P00519 4/20 0.57
CYP11B2 P19099 2/20 0.56
CYP11B1 P15538 1/20 0.56
MKNK1 Q9BUB5 6/20 0.55
MKNK2 Q9HBH9 6/20 0.55
OPRM1 P35372 1/20 0.54
KCNH2 Q12809 1/20 0.54
RIPK1 Q13546 1/20 0.51
AURKA O14965 1/20 0.50
TPX2 Q9ULW0 1/20 0.50
ALPL P05186 1/20 0.48
PRMT6 Q96LA8 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1758378 0.99 SCN10A (0.61) SCN10AMAP4K4ABL1CYP11B2CYP11B1
SCHEMBL27995027 0.88 CYP11B2 (0.55) SCN10AMAP4K4ABL1CYP11B2CYP11B1
SCHEMBL28129364 0.88 CYP11B2 (0.55) SCN10AMAP4K4ABL1CYP11B2CYP11B1
SCHEMBL27995243 0.88 CYP11B2 (0.59) SCN10AMAP4K4ABL1CYP11B2CYP11B1
SCHEMBL25003797 0.84 SCN10A (0.67) SCN10AABL1OPRM1KCNH2AURKA
SCHEMBL640664 0.83 SCN10A (0.67) SCN10AMAP4K4ABL1CYP11B2CYP11B1
SCHEMBL9606759 0.81 SCN10A (0.61) SCN10AMAP4K4ABL1CYP11B2CYP11B1
SCHEMBL30602765 0.81 SIRT2 (0.50) SCN10AABL1CYP11B2CYP11B1MKNK1
SCHEMBL8297933 0.80 ABL1 (0.56) MAP4K4ABL1AURKATPX2
SCHEMBL641681 0.80 SCN10A (0.63) SCN10AABL1CYP11B2CYP11B1OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104379574-B For suppressing the heterocyclic carbamate derivatives of the activity of ABL1, ABL2 and BCR ABL1 诺华股份有限公司 2017-03-01 CN disclosed
CN-104334529-A Compounds and compositions for inhibiting the activity of ABL1, ABL2, and BCR-ABL1 NOVARTIS AG 2015-02-04 CN disclosed